JL
Juan josé Lasarte
Principal Investigator
University of Navarra
I'm working on
9 months ago
Cancer immunotherapy, cell engineering, tumor microenvironment
About
My work focuses on cancer immunotherapy: engineering CAR-T cells, modulating T-cell regulation and innate signals, and reprogramming the tumor microenvironment. We deploy peptide and nanoparticle delivery and checkpoint combinations, translating viral immunology into therapies.
Systemic Inflammation in Hip Fracture and Osteoarthritis: Insights into Pathways of Immunoporosis
International Journal of Molecular Sciences
•2025
Reprogramming CAR-T cells: Targeting SLC transporters for tumor microenvironment adaptation
Pharmacological Research
•2025
Impact of medication use on olfactory performance in older adults
Frontiers in Public Health
•2025
Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells
J Immunother Cancer .
•2022
Topical application of a peptide inhibitor of transforming growth factor-β1 ameliorates bleomycin-induced skin fibrosis
Journal of Investigative Dermatology 125 (3), 450-455, 2005
A combined PD-1/C5a blockade synergistically protects against lung cancer growth and metastasis
Cancer discovery 7 (7), 694-703, 2017
Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses
Journal of virology 77 (20), 10862-10871, 2003
Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression
Nature medicine 25 (7), 1073-1081, 2019
Is plasma cardiotrophin-1 a marker of hypertensive heart disease?
Journal of hypertension 23 (3), 625-632, 2005
Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies
Nature communications 8 (1), 15424, 2017
Poly (anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation
Clinical and Vaccine Immunology 17 (9), 1356-1362, 2010
Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model
Cancer Immunology, Immunotherapy 68, 379-393, 2019
Upregulation of indoleamine 2, 3-dioxygenase in hepatitis C virus infection
Journal of virology 81 (7), 3662-3666, 2007
The extra domain A from fibronectin targets antigens to TLR4-expressing cells and induces cytotoxic T cell responses in vivo
The Journal of Immunology 178 (2), 748-756, 2007
A synthetic peptide from transforming growth factor-β1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats
Cardiovascular research 81 (3), 601-609, 2009
A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice
The Journal of Immunology 185 (9), 5150-5159, 2010
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
Journal of hepatology 59 (1), 81-88, 2013
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Journal for immunotherapy of cancer 8 (1), 2020
Contribution of IL-17–producing γδ T cells to the efficacy of anticancer chemotherapy
Journal of Experimental Medicine 208 (3), 491-503, 2011
Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression
The Journal of Immunology 189 (9), 4674-4683, 2012
CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-γ-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by …
The Journal of Immunology 171 (11), 5931-5939, 2003
Transmission of hepatitis C virus infection to tree shrews
Virology 244 (2), 513-520, 1998
Abnormal Priming of CD4+ T Cells by Dendritic Cells Expressing Hepatitis C Virus Core and E1 Proteins
Journal of virology 76 (10), 5062-5070, 2002
No funding yet
This innovator hasn't added funding yet. In the meantime, you might want to explore their publications, patents, and other profile details.
No patents yet
This innovator hasn't added patents yet. In the meantime, you might want to explore their publications, funding, and other profile details.
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.
delivered to your inbox.
© 2026 Halo Cures, Inc.